| 12001 | eosinophil (fraction, minimum, inv-norm transformed) | GCST90475303 | 2.58e-03 |
| 12002 | CSF3 levels | GCST90468886 | 2.57e-03 |
| 12003 | DRAXIN levels | GCST90469038 | 2.57e-03 |
| 12004 | MAVS/TBL1X ratio | GCST90315399 | 2.57e-03 |
| 12005 | CST5 levels | GCST90468895 | 2.56e-03 |
| 12006 | Educational attainment (confirmatory factor analysis Factor 10) | GCST90309344 | 2.56e-03 |
| 12007 | LAMP3/PRSS8 ratio | GCST90315275 | 2.55e-03 |
| 12008 | SUSD4 levels | GCST90470788 | 2.51e-03 |
| 12009 | Psoriasis vulgaris (PheCode 696.41) | GCST90476190 | 2.49e-03 |
| 12010 | IL5RA levels | GCST90469600 | 2.48e-03 |
| 12011 | 1-stearoylglycerophosphoethanolamine levels | GCST90243780 | 2.47e-03 |
| 12012 | SPINT1/SUSD2 ratio | GCST90315878 | 2.46e-03 |
| 12013 | Chronic lower respiratory diseases | FING00000290 | 2.45e-03 |
| 12014 | DTI autoptx MD fmi tract | GCST90385231 | 2.45e-03 |
| 12015 | EBAG9/EDAR ratio | GCST90314563 | 2.45e-03 |
| 12016 | Essential tremor (PheCode 333.1) | GCST90475832 | 2.45e-03 |
| 12017 | Phosphatidylcholine-O_40:5_[M+H]1+/Phosphatidylcholine-P_40:4_[M+H]1+ levels | GCST90060423 | 2.44e-03 |
| 12018 | Blood cell traits latent factor 22 (white cell) | GCST90559264 | 2.44e-03 |
| 12019 | AMY1A or AMY1B or AMY1C levels | GCST90468297 | 2.43e-03 |
| 12020 | HLAE/IL15 ratio | GCST90315061 | 2.43e-03 |
| 12021 | Blood cell traits latent factor 17 (white cell) | GCST90559259 | 2.43e-03 |
| 12022 | Occupational attainment | GCST90102253 | 2.40e-03 |
| 12023 | DBNL/VASH1 ratio | GCST90314427 | 2.39e-03 |
| 12024 | F2R/TNFRSF14 ratio | GCST90314739 | 2.39e-03 |
| 12025 | CRELD2/HYOU1 ratio | GCST90314255 | 2.39e-03 |
| 12026 | Malignant neoplasm of kidney, except pelvis (PheCode 189.11) | GCST90475597 | 2.39e-03 |
| 12027 | CD48/SLAMF7 ratio | GCST90313842 | 2.39e-03 |
| 12028 | GP1BA/SELP ratio | GCST90314958 | 2.38e-03 |
| 12029 | Acute bronchitis | FING00000021 | 2.37e-03 |
| 12030 | Attention deficit hyperactivity disorder | GCST90568441 | 2.36e-03 |
| 12031 | FLT3LG levels | GCST90469250 | 2.33e-03 |
| 12032 | Diabetes | GCST90468124 | 2.32e-03 |
| 12033 | Clonal hematopoiesis (DNMT3A mutation) | GCST90435354 | 2.32e-03 |
| 12034 | ACY1/DCXR ratio | GCST90313162 | 2.31e-03 |
| 12035 | TNFRSF13B/TNFRSF13C ratio | GCST90315931 | 2.31e-03 |
| 12036 | KLKB1 levels | GCST90469708 | 2.31e-03 |
| 12037 | Functional dyspepsia | FING00000561 | 2.30e-03 |
| 12038 | CES2 levels | GCST90468719 | 2.30e-03 |
| 12039 | Sacroiliitis, not elsewhere classified | FING00001273 | 2.29e-03 |
| 12040 | TNFRSF13B/TNFSF13B ratio | GCST90315933 | 2.28e-03 |
| 12041 | Psoriasis (PheCode 696.4) | GCST90476187 | 2.27e-03 |
| 12042 | EDAR/YES1 ratio | GCST90314594 | 2.26e-03 |
| 12043 | CLEC4G/KEL ratio | GCST90314119 | 2.25e-03 |
| 12044 | DTI autoptx MD ifo r tract | GCST90385233 | 2.25e-03 |
| 12045 | Subclinical hypothyroidism in pregnancy | GCST90435197 | 2.22e-03 |
| 12046 | Omega-6 fatty acid levels | GCST90502518 | 2.21e-03 |
| 12047 | Thyrotoxicosis with diffuse goitre | FING00001361 | 2.20e-03 |
| 12048 | Primary biliary cholangitis | GCST90061440 | 2.20e-03 |
| 12049 | FCRL1 levels | GCST90469205 | 2.20e-03 |
| 12050 | Other specified disorders of external ear | FING00001104 | 2.20e-03 |
| 12051 | APRT/EREG ratio | GCST90313335 | 2.19e-03 |
| 12052 | CRELD2/NUCB2 ratio | GCST90314256 | 2.19e-03 |
| 12053 | Malignant melanoma, excluding all cancers (controls excluding all cancers) | FING00000750 | 2.17e-03 |
| 12054 | Operation code - cholecystectomy/gall bladder removal | Operations | UKBB00000554 | 2.15e-03 |
| 12055 | Diabetes diagnosed by doctor | Medical conditions | UKBB00000168 | 2.13e-03 |
| 12056 | Psoriasis and related disorder (PheCode 696) | GCST90476186 | 2.13e-03 |
| 12057 | Basophil count | GCST90018726 | 2.12e-03 |
| 12058 | Mean spheric corpuscular volume | GCST90002397 | 2.11e-03 |
| 12059 | GP1BA/HBEGF ratio | GCST90314956 | 2.11e-03 |
| 12060 | CD40LG/EDAR ratio | GCST90313818 | 2.10e-03 |
| 12061 | Other acute lower respiratory infections | FING00000921 | 2.10e-03 |
| 12062 | Asthma (more control exclusions) | FING00000113 | 2.09e-03 |
| 12063 | Platelet crit (UKB data field 30090) | GCST90468096 | 2.09e-03 |
| 12064 | REG1B/REG3A ratio | GCST90315765 | 2.08e-03 |
| 12065 | Mean corpuscular volume | GCST90002392 | 2.08e-03 |
| 12066 | EDAR/PRDX5 ratio | GCST90314583 | 2.08e-03 |
| 12067 | REST UKBBICA NODEamps25 0001 | GCST90385484 | 2.07e-03 |
| 12068 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T464 | ECGA000464 | 2.07e-03 |
| 12069 | Rheumatoid arthritis | GCST90132223 | 2.07e-03 |
| 12070 | LYN/SIRT2 ratio | GCST90315349 | 2.06e-03 |
| 12071 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T462 | ECGU000462 | 2.06e-03 |
| 12072 | MYL3 levels | GCST90469977 | 2.04e-03 |
| 12073 | DSC2 levels | GCST90469040 | 2.04e-03 |
| 12074 | CNST/DOK2 ratio | GCST90314157 | 2.03e-03 |
| 12075 | CD163/FOLR2 ratio | GCST90313734 | 2.01e-03 |
| 12076 | CLSTN3 levels | GCST90468790 | 2.01e-03 |
| 12077 | Oral glucose tolerance test-1h | GCST90566422 | 2.00e-03 |
| 12078 | KDM3A levels | GCST90469671 | 2.00e-03 |
| 12079 | NID1/SORT1 ratio | GCST90315542 | 2.00e-03 |
| 12080 | OSCAR levels | GCST90470131 | 1.99e-03 |
| 12081 | TNFRSF11A levels | GCST90470902 | 1.96e-03 |
| 12082 | Disorders of the thyroid gland | FING00000463 | 1.95e-03 |
| 12083 | ERBB4/UMOD ratio | GCST90314692 | 1.94e-03 |
| 12084 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502068 | 1.94e-03 |
| 12085 | Clonal hematopoiesis (overall) | GCST90435353 | 1.93e-03 |
| 12086 | SEPTIN3 levels | GCST90470576 | 1.93e-03 |
| 12087 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 1.92e-03 |
| 12088 | FCRL5/ICAM3 ratio | GCST90314802 | 1.92e-03 |
| 12089 | Mean reticulocyte volume | GCST90002396 | 1.90e-03 |
| 12090 | F2R/SEMA4D ratio | GCST90314734 | 1.90e-03 |
| 12091 | Glycated haemoglobin (HbA1c) | Blood biochemistry | UKBB00000289 | 1.89e-03 |
| 12092 | Free thyroxine levels within normal range in pregnancy | GCST90435196 | 1.89e-03 |
| 12093 | APBB1IP/NADK ratio | GCST90313298 | 1.88e-03 |
| 12094 | Omega-3 fatty acids to total fatty acids percentage | GCST90502087 | 1.87e-03 |
| 12095 | CD58/SIRPB1 ratio | GCST90313855 | 1.87e-03 |
| 12096 | Repeated disturbing thoughts of stressful experience in past month | Traumatic events | UKBB00000750 | 1.87e-03 |
| 12097 | Thyroid problems | GCST90475276 | 1.86e-03 |
| 12098 | Spondyloarthritis | FING00001323 | 1.86e-03 |
| 12099 | GGH levels | GCST90469335 | 1.85e-03 |
| 12100 | OSM levels | GCST90470133 | 1.84e-03 |
| 12101 | Migraine headaches | GCST90475546 | 1.82e-03 |
| 12102 | White blood cell count (basophil) | GCST004618 | 1.82e-03 |
| 12103 | Other noninfective gastroenteritis and colitis | FING00001077 | 1.81e-03 |
| 12104 | Neutrophil count | GCST90018748 | 1.81e-03 |
| 12105 | BLNK levels | GCST90468448 | 1.81e-03 |
| 12106 | Handedness (chirality/laterality) - Left-handed | Early life factors | UKBB00000302 | 1.80e-03 |
| 12107 | Hypothyroidism | GCST90204167 | 1.80e-03 |
| 12108 | Mean reticulocyte volume | Blood count | UKBB00000451 | 1.78e-03 |
| 12109 | Platelet crit | Blood count | UKBB00000647 | 1.78e-03 |
| 12110 | CA14 levels | GCST90468509 | 1.77e-03 |
| 12111 | CRISP3 levels | GCST90468866 | 1.77e-03 |
| 12112 | Cancer code, self-reported - basal cell carcinoma | Medical conditions | UKBB00000117 | 1.76e-03 |
| 12113 | Taking other prescription medications | Medication | UKBB00000813 | 1.76e-03 |
| 12114 | Asthma-related pneumonia | FING00000119 | 1.76e-03 |
| 12115 | CD5/CD6 ratio | GCST90313860 | 1.76e-03 |
| 12116 | MAMDC4 levels | GCST90469842 | 1.76e-03 |
| 12117 | eosinophil (absolute count, minimum, inv-norm transformed) | GCST90475294 | 1.76e-03 |
| 12118 | SIGLEC8 levels | GCST90470636 | 1.75e-03 |
| 12119 | Right-hemisphere control network to accumbens white-matter structural connectivity | GCST90302842 | 1.75e-03 |
| 12120 | CCN2/HBEGF ratio | GCST90313713 | 1.74e-03 |
| 12121 | Self-rated health | GCST006620 | 1.74e-03 |
| 12122 | DLL1/NBL1 ratio | GCST90314496 | 1.72e-03 |
| 12123 | CD244/TREML2 ratio | GCST90313767 | 1.72e-03 |
| 12124 | Mean reticulocyte volume | GCST90025975 | 1.72e-03 |
| 12125 | MCTS1 levels | GCST90469874 | 1.70e-03 |
| 12126 | Avoided activities or situations because of previous stressful experience in past month | Traumatic events | UKBB00000083 | 1.68e-03 |
| 12127 | Plasma argininate* levels in chronic kidney disease | GCST90264826 | 1.65e-03 |
| 12128 | DAB2/ERBIN ratio | GCST90314361 | 1.65e-03 |
| 12129 | APBB1IP levels | GCST90468327 | 1.64e-03 |
| 12130 | BSG/LY9 ratio | GCST90313534 | 1.64e-03 |
| 12131 | IL2RA levels | GCST90469585 | 1.63e-03 |
| 12132 | PIGR levels | GCST90470232 | 1.63e-03 |
| 12133 | Melanoma | GCST90011809 | 1.62e-03 |
| 12134 | CCL5/SELP ratio | GCST90313705 | 1.62e-03 |
| 12135 | Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044) | GCST90042535 | 1.62e-03 |
| 12136 | PRTN3 levels | GCST90470348 | 1.61e-03 |
| 12137 | EDAR/ENO2 ratio | GCST90314574 | 1.61e-03 |
| 12138 | Weight | GCST90278650 | 1.61e-03 |
| 12139 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 1.61e-03 |
| 12140 | CXCL11 levels | GCST90468924 | 1.60e-03 |
| 12141 | TNFRSF10B levels | GCST90470900 | 1.60e-03 |
| 12142 | neutrophil (fraction, maximum, inv-norm transformed) | GCST90475535 | 1.60e-03 |
| 12143 | Psoriatic arthritis | GCST90243956 | 1.59e-03 |
| 12144 | REG1A/REG3A ratio | GCST90315761 | 1.59e-03 |
| 12145 | HNRNPK/VASH1 ratio | GCST90315071 | 1.59e-03 |
| 12146 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 1.57e-03 |
| 12147 | Patient classification on admission (recoded) - Inpatient | Summary Administration | UKBB00000637 | 1.57e-03 |
| 12148 | GOLM2 levels | GCST90469376 | 1.54e-03 |
| 12149 | Basophil percentage of white cells | GCST004631 | 1.53e-03 |
| 12150 | DBNL/EDAR ratio | GCST90314416 | 1.52e-03 |
| 12151 | CD69/CHMP1A ratio | GCST90313868 | 1.52e-03 |
| 12152 | CD5L levels | GCST90468640 | 1.52e-03 |
| 12153 | ICAM3/TNFRSF13B ratio | GCST90315124 | 1.50e-03 |
| 12154 | Uterine fibroids | GCST90468154 | 1.50e-03 |
| 12155 | Rheumatoid arthritis | GCST90018690 | 1.46e-03 |
| 12156 | CRTAM levels | GCST90468871 | 1.46e-03 |
| 12157 | DAG1/HBEGF ratio | GCST90314376 | 1.45e-03 |
| 12158 | BAG6/BMP6 ratio | GCST90313450 | 1.45e-03 |
| 12159 | DEFA1 or DEFA1B levels | GCST90468979 | 1.45e-03 |
| 12160 | F-meat liking (derived food-liking factor) | GCST90094799 | 1.43e-03 |
| 12161 | Mean reticulocyte volume (UKB data field 30260) | GCST90468088 | 1.42e-03 |
| 12162 | CD48/CRTAM ratio | GCST90313839 | 1.42e-03 |
| 12163 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 1.42e-03 |
| 12164 | Alcohol intake versus 10 years previously | Alcohol | UKBB00000024 | 1.41e-03 |
| 12165 | LPO levels | GCST90469789 | 1.39e-03 |
| 12166 | ERBB2/GUSB ratio | GCST90314687 | 1.37e-03 |
| 12167 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 1.37e-03 |
| 12168 | F2R levels | GCST90469168 | 1.37e-03 |
| 12169 | METAP2/RILP ratio | GCST90315433 | 1.36e-03 |
| 12170 | CRISP2 levels | GCST90468865 | 1.33e-03 |
| 12171 | IFNLR1 levels | GCST90469518 | 1.33e-03 |
| 12172 | Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditions | UKBB00000369 | 1.33e-03 |
| 12173 | CTSB levels | GCST90468908 | 1.32e-03 |
| 12174 | LAYN/ULBP2 ratio | GCST90315292 | 1.30e-03 |
| 12175 | CXCL5/EDAR ratio | GCST90314349 | 1.29e-03 |
| 12176 | Red wine consumption (glasses per month) (UKB data field 1578, 4419) | GCST90132987 | 1.29e-03 |
| 12177 | Cheese intake | Diet | UKBB00000127 | 1.29e-03 |
| 12178 | Mean corpuscular volume | GCST004602 | 1.28e-03 |
| 12179 | KEL levels | GCST90469673 | 1.27e-03 |
| 12180 | HBEGF/PDGFB ratio | GCST90315034 | 1.27e-03 |
| 12181 | Alanine levels | GCST90497085 | 1.26e-03 |
| 12182 | MYLPF levels | GCST90469980 | 1.25e-03 |
| 12183 | Treatment/medication code - metformin | Medications | UKBB00000851 | 1.25e-03 |
| 12184 | FGF2/HBEGF ratio | GCST90314811 | 1.25e-03 |
| 12185 | GHRL levels | GCST90469341 | 1.25e-03 |
| 12186 | Overweight, obesity and other hyperalimentation | endocrine/metabolic | UKBB00000622 | 1.25e-03 |
| 12187 | LY9 levels | GCST90469824 | 1.24e-03 |
| 12188 | Hypothyroidism, strict autoimmune | FING00000656 | 1.23e-03 |
| 12189 | CRTAM/VCAM1 ratio | GCST90314281 | 1.23e-03 |
| 12190 | Clonal haematopoiesis of indeterminate potential (with or without mosaic chromosomal alteration) | GCST90165267 | 1.22e-03 |
| 12191 | Red blood cell count | GCST90278641 | 1.21e-03 |
| 12192 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 1.21e-03 |
| 12193 | Disorders of bilirubin excretion (PheCode 277.4) | GCST90475756 | 1.21e-03 |
| 12194 | TNFRSF13C/TNFSF13B ratio | GCST90315934 | 1.19e-03 |
| 12195 | NADK/PXN ratio | GCST90315512 | 1.17e-03 |
| 12196 | TNFRSF6B levels | GCST90470914 | 1.16e-03 |
| 12197 | Mosaic chromosomal alteration of the Y chromosome | GCST90165289 | 1.15e-03 |
| 12198 | mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed) | GCST90475442 | 1.15e-03 |
| 12199 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475450 | 1.14e-03 |
| 12200 | ADGRE5/SEMA7A ratio | GCST90313183 | 1.14e-03 |
| 12201 | Coeliac disease | FING00000312 | 1.14e-03 |
| 12202 | IL5RA/TNFRSF13B ratio | GCST90315164 | 1.13e-03 |
| 12203 | Cheese consumption | GCST90133000 | 1.13e-03 |
| 12204 | PRG3 levels | GCST90470323 | 1.13e-03 |
| 12205 | Blood cell traits latent factor 18 (platelet) | GCST90559260 | 1.12e-03 |
| 12206 | PDCD1 levels | GCST90470181 | 1.11e-03 |
| 12207 | Oral glucose tolerance test-0h | GCST90566421 | 1.11e-03 |
| 12208 | IDP T1 SIENAX peripheral grey unnormalised volume | GCST90002427 | 1.08e-03 |
| 12209 | EDAR/F11R ratio | GCST90314576 | 1.07e-03 |
| 12210 | Late-onset myasthenia gravis | GCST90093466 | 1.07e-03 |
| 12211 | CD244/CRTAM ratio | GCST90313763 | 1.06e-03 |
| 12212 | ST6GAL1 levels | GCST90470753 | 1.05e-03 |
| 12213 | DAG1/F2R ratio | GCST90314374 | 1.04e-03 |
| 12214 | Hypothyroidism | GCST90468138 | 1.04e-03 |
| 12215 | FASLG levels | GCST90469191 | 1.03e-03 |
| 12216 | Red blood cell count | GCST90002364 | 1.03e-03 |
| 12217 | ICAM3/SLAMF7 ratio | GCST90315123 | 1.03e-03 |
| 12218 | Mean corpuscular hemoglobin | GCST90002390 | 1.03e-03 |
| 12219 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475446 | 1.02e-03 |
| 12220 | Obesity | endocrine/metabolic | UKBB00000544 | 1.01e-03 |
| 12221 | DAPP1/ITGB1BP2 ratio | GCST90314388 | 9.89e-04 |
| 12222 | Squamous cell neoplasms and carcinomas of the skin, excluding all cancers (controls excluding all cancers) | FING00001330 | 9.87e-04 |
| 12223 | ARHGAP30 levels | GCST90468354 | 9.80e-04 |
| 12224 | Primary sclerosing cholangitis | GCST004030 | 9.74e-04 |
| 12225 | GALNT5 levels | GCST90469298 | 9.73e-04 |
| 12226 | Obesity | Obesity and other hyperalimentation | UKBB00000545 | 9.53e-04 |
| 12227 | Glucose levels | GCST90092819 | 9.53e-04 |
| 12228 | FAM3B/FUT3_FUT5 ratio | GCST90314777 | 9.35e-04 |
| 12229 | CKAP4/TNFRSF4 ratio | GCST90314076 | 9.23e-04 |
| 12230 | CXCL5/PLXNA4 ratio | GCST90314351 | 9.16e-04 |
| 12231 | RNASET2 levels | GCST90470481 | 9.09e-04 |
| 12232 | Follicular lymphoma, hilmo (controls excluding all cancers) | FING00000548 | 9.05e-04 |
| 12233 | Ankylosing spondylitis | FING00000089 | 8.98e-04 |
| 12234 | CD244 levels | GCST90468611 | 8.94e-04 |
| 12235 | Thyrotoxicosis | FING00001360 | 8.89e-04 |
| 12236 | CD6/EZR ratio | GCST90313890 | 8.85e-04 |
| 12237 | EDAR/SERPINB1 ratio | GCST90314586 | 8.57e-04 |
| 12238 | Mean corpuscular volume | GCST90002335 | 8.36e-04 |
| 12239 | CCL19 levels | GCST90468571 | 8.28e-04 |
| 12240 | EPHB6/VWC2 ratio | GCST90314683 | 8.16e-04 |
| 12241 | GDF15 levels | GCST90469321 | 8.01e-04 |
| 12242 | Red blood cell count | GCST90018751 | 7.92e-04 |
| 12243 | TPSAB1 levels | GCST90470951 | 7.68e-04 |
| 12244 | GZMA levels | GCST90469423 | 7.66e-04 |
| 12245 | SLAMF7 levels | GCST90470651 | 7.66e-04 |
| 12246 | T1 CAT WM unnormalised volume | GCST90383983 | 7.59e-04 |
| 12247 | APP/HBEGF ratio | GCST90313324 | 7.54e-04 |
| 12248 | HBEGF/SDC4 ratio | GCST90315037 | 7.49e-04 |
| 12249 | NFATC1/SPRY2 ratio | GCST90315539 | 7.47e-04 |
| 12250 | CXCL11/SDC4 ratio | GCST90314336 | 7.41e-04 |
| 12251 | Mean corpuscular volume | Blood count | UKBB00000449 | 7.30e-04 |
| 12252 | VSTM1 levels | GCST90471055 | 7.29e-04 |
| 12253 | CXCL11/DKK1 ratio | GCST90314334 | 7.26e-04 |
| 12254 | TNF levels | GCST90470924 | 7.20e-04 |
| 12255 | Mean corpuscular haemoglobin | Blood count | UKBB00000447 | 7.01e-04 |
| 12256 | EZR levels | GCST90469162 | 7.00e-04 |
| 12257 | EFNA4 levels | GCST90469081 | 6.95e-04 |
| 12258 | Physical activity | GCST90093324 | 6.93e-04 |
| 12259 | Mean corpuscular haemoglobin (UKB data field 30050) | GCST90468084 | 6.82e-04 |
| 12260 | Myasthenia gravis | GCST90093061 | 6.77e-04 |
| 12261 | IL16 levels | GCST90469557 | 6.70e-04 |
| 12262 | FCAR levels | GCST90469197 | 6.63e-04 |
| 12263 | Hypothyroidism | GCST90319320 | 6.62e-04 |
| 12264 | CLEC1A levels | GCST90468767 | 6.44e-04 |
| 12265 | CD6 levels | GCST90468644 | 6.32e-04 |
| 12266 | All pneumoniae | FING00000065 | 6.30e-04 |
| 12267 | Mean corpuscular volume | GCST90018746 | 6.27e-04 |
| 12268 | Hypothyroidism (PheCode 244) | GCST90475647 | 6.22e-04 |
| 12269 | MMP8/OLR1 ratio | GCST90315464 | 6.12e-04 |
| 12270 | Mean corpuscular hemoglobin | GCST90002323 | 6.02e-04 |
| 12271 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476349 | 5.98e-04 |
| 12272 | Non-cancer illness code, self-reported - diabetes | Medical conditions | UKBB00000508 | 5.93e-04 |
| 12273 | KLRD1 levels | GCST90469711 | 5.71e-04 |
| 12274 | CD72 levels | GCST90468646 | 5.70e-04 |
| 12275 | IL16/NADK ratio | GCST90315152 | 5.69e-04 |
| 12276 | Takes medication for Thyroid problems? | GCST90475277 | 5.59e-04 |
| 12277 | CC2D1A/STAMBP ratio | GCST90313664 | 5.58e-04 |
| 12278 | TNFRSF13C levels | GCST90470906 | 5.53e-04 |
| 12279 | Red blood cell (erythrocyte) count | Blood count | UKBB00000747 | 5.24e-04 |
| 12280 | IL1RN levels | GCST90469576 | 5.12e-04 |
| 12281 | Mean corpuscular hemoglobin | GCST004630 | 5.02e-04 |
| 12282 | Hypothyroidism NOS (PheCode 244.4) | GCST90475653 | 4.77e-04 |
| 12283 | CFHR4 levels | GCST90468727 | 4.46e-04 |
| 12284 | ADA2 levels | GCST90468215 | 4.39e-04 |
| 12285 | T1 CAT GM unnormalised volume | GCST90383982 | 4.28e-04 |
| 12286 | COPD/asthma/ILD related infections | FING00000353 | 4.19e-04 |
| 12287 | ICAM3 levels | GCST90469500 | 4.13e-04 |
| 12288 | Telomere length (principal component 1) | GCST90435144 | 4.06e-04 |
| 12289 | CD48 levels | GCST90468635 | 3.82e-04 |
| 12290 | VMO1 levels | GCST90471042 | 3.81e-04 |
| 12291 | GCNT1 levels | GCST90469319 | 3.72e-04 |
| 12292 | Oral glucose tolerance test-0h | GCST90297788 | 3.36e-04 |
| 12293 | Red blood cell count | GCST90002403 | 3.27e-04 |
| 12294 | Influenza and pneumonia | FING00000679 | 2.95e-04 |
| 12295 | Red blood cell erythrocyte count (UKB data field 30010) | GCST90468098 | 2.94e-04 |
| 12296 | APBB1IP/POLR2F ratio | GCST90313300 | 2.92e-04 |
| 12297 | PRG2 levels | GCST90470322 | 2.70e-04 |
| 12298 | MANSC1/PODXL2 ratio | GCST90315371 | 2.62e-04 |
| 12299 | CLEC4G levels | GCST90468774 | 2.56e-04 |
| 12300 | CLEC4C levels | GCST90468772 | 2.52e-04 |
| 12301 | ADAM8 levels | GCST90468220 | 2.39e-04 |
| 12302 | Mean corpuscular hemoglobin | GCST90018744 | 2.24e-04 |
| 12303 | Takes medication for skin cancer? | GCST90475190 | 2.23e-04 |
| 12304 | TG levels | GCST90470851 | 2.06e-04 |
| 12305 | CLEC7A levels | GCST90468778 | 2.06e-04 |
| 12306 | Red blood cell count | GCST004601 | 2.01e-04 |
| 12307 | IDP T1 SIENAX grey unnormalised volume | GCST90002431 | 1.91e-04 |
| 12308 | Breast cancer (triple negative or BRCA1-positive) | GCST010100 | 1.64e-04 |
| 12309 | S100P levels | GCST90470520 | 9.18e-05 |
| 12310 | Mineral and other dietary supplements - Calcium | Medication | UKBB00000471 | 8.68e-05 |
| 12311 | red blood cell count (RBC, maximum, inv-norm transformed) | GCST90476345 | 5.82e-05 |
| 12312 | red blood cell count (RBC, minimum, inv-norm transformed) | GCST90476353 | 3.05e-05 |
| 12313 | CEBPB/NADK ratio | GCST90314006 | 2.32e-05 |